2 Cancer Drugs Reverse Alzheimer's Damage in Mice, Opening Faster Path to Human Trials
Updated
Updated · ScienceAlert · Jun 8
2 Cancer Drugs Reverse Alzheimer's Damage in Mice, Opening Faster Path to Human Trials
1 articles · Updated · ScienceAlert · Jun 8
Summary
Letrozole and Irinotecan—two FDA-approved cancer drugs—reduced tau buildup and improved learning and memory when used together in mouse models of Alzheimer's disease.
US researchers identified the pair by matching Alzheimer's-linked gene-expression changes with drugs that reverse those patterns, then checking cancer patient records where the medicines were tied to lower Alzheimer's risk.
The combination appeared to work across different brain cell types: letrozole mainly in neurons and irinotecan in glia, supporting a multi-target approach to a disease that has resisted single-drug strategies.
Human testing has not begun, and both drugs carry side effects, but existing US approvals could speed clinical trials if the mouse findings hold up.
More than 55 million people worldwide have Alzheimer's, and that total is expected to more than double over the next 25 years.
AI found this Alzheimer's breakthrough. What other incurable diseases could be solved by repurposing old drugs?
Cancer drugs may treat Alzheimer's. What is the hidden biological link between these opposite diseases?
Multi-Target Drug Repurposing for Alzheimer’s: Letrozole and Irinotecan Show Preclinical Success, Human Trials on Horizon
Overview
As of June 2026, a multidisciplinary team at UCSF has identified a promising new approach for Alzheimer’s disease by repurposing two FDA-approved cancer drugs, letrozole and irinotecan. Using a novel computational method that combined single-cell data, drug databases, and real-world medical records, the team found these drugs were linked to lower Alzheimer’s risk. When tested in mice with Alzheimer’s-like symptoms, the drug combination reversed brain degeneration and improved memory. These strong preclinical results support further exploration of multi-target drug strategies for Alzheimer’s and lay the groundwork for future human trials.